The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Recent research out of Cornell University showed that GLP-1 users' grocery bills have been reduced by as much as 8.6% — with ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to treat Type 2 diabetes and obesity. Recent research has expanded their potential applications ...

Losing weight on a GLP-1 medication can have emotional and physical effects. Some changes are easier to handle than others, ...

Background/Aims Studies in animals suggest a physiological role for glucagon-like peptide-1-(7–36)-amide (GLP-1) in regulating satiety. The role of GLP-1 in regulating food intake in man has, however, ...

The glucagon-like peptides GLP-1 and GLP-2 are synthesised and then released from enteroendocrine cells in the small and large intestine. GLP-1 promotes efficient nutrient assimilation while GLP-2 ...

Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are secreted from the same intestinal cells following meal ingestion. GLP-1 is now widely recognised to reduce blood glucose levels ...

4 China Medical University College of Chinese Medicine, Taichung, Taiwan Background Clinical studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RA) can have beneficial effects on ...